PROSPR VITAL-H plans a phase 3 hybrid trial of repurposed drugs to establish a regulatory path for testing therapeutics for aging.

Provenance

First verified

2026-02-24

Source date (award start)

2026-02-24

Revision state

Version 1.1 records the September 3, 2026 re-verification and clarifies that the trial is prospective and existing drug approvals do not establish an aging or healthspan indication or result.

Last verified

2026-09-03

Status

Prospective phase 3 hybrid trial · no results reported

Freshness

Current

Version

1.1

Fingerprint

d17aae30b9e29769

Change sensitivity

High

Evidence limits

Existing approvals for the repurposed drugs do not establish approval for aging or healthspan. The source reports no enrollment, effect, safety finding, new indication, or regulatory result.

Primary source

https://arpa-h.gov/explore-funding/awards/4176

Related signals

• SIG-2026-007 — PROSPR VITAL-H will test repurposed drugs in a phase 3 hybrid aging trial